Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nelarabine

Next Previous
X
Search
Drug Profile

Nelarabine

Alternative Names: 506U; 506U78; Arranon; Atriance; C 506; Compound 506; GW 506U; GW 506U78; Nelzarabine

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer National Cancer Institute (USA); Novartis
  • Class Antineoplastics; Arabinonucleosides; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 14 Jul 2017 No recent reports on development identified - Phase-I/II for Acute lymphoblastic leukaemia and T-cell lymphoma (Combination therapy, Second-line therapy or greater) in Australia, Canada, Austria, France, Italy, Netherlands, United Kingdom and USA (IV)
  • 04 Jun 2015 Nelarabine is still in phase III development for Acute lymphoblastic leukaemia (Combination therapy, First-line therapy) and T-cell lymphoma (Combination therapy, First-line therapy) in Australia, Canada, New Zealand, Switzerland and USA
  • 04 Jun 2015 Nelarabine is still in phase I/II development for Acute lymphoblastic leukaemia (Combination therapy, Second-line therapy or greater) and T-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA, Canada, Australia, Austria, France, Italy and Netherlands

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top